Drug intelligence / Profile preview

VRC4302

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

VRC4302 is a first-generation HIV-1 DNA plasmid vaccine candidate (9170 bp) developed by inserting HIV-1 genes into the pVR1012x/s plasmid backbone. It encodes modified gag-pol proteins from HIV-1, designed to stimulate an immune response without causing infection. The vaccine contains deletions in the protease-, RT-, and integrase-coding regions to eliminate biological activities of these viral proteins for safety reasons.

Beyond the preview

Go deeper on VRC4302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC4302.